Classifying leprosy patients - Searching for the perfect solution?

Leprosy Review

Volumn 78, Issue 4, 2007, Pages 317-320

  Lockwood, Diana N J ^a   Sarno, Euzenir ^b   Smith, W Cairns ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; LEPROSTATIC AGENT;

BORDERLINE LEPROSY; DISEASE CLASSIFICATION; DISEASE TRANSMISSION; EDITORIAL; ERYTHEMA NODOSUM LEPROSUM; HEALTH SERVICE; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; LEPROSY; MULTIBACILLARY LEPROSY; MYCOBACTERIUM LEPRAE; PATHOGENESIS; PAUCIBACILLARY LEPROSY; SKIN EXAMINATION; SKIN TEST;

DRUG ADMINISTRATION SCHEDULE; HUMANS; LEPROSTATIC AGENTS; LEPROSY; SEVERITY OF ILLNESS INDEX;

EID: 38649097174     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (18)

1. Pocaterra L, Jain S, Reddy R, Muzaffarullah S, Torres O, Suneetha S et al. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India. Am J Trop Med Hyg, 2006; 74: 868-879.
2. Nery JA, Vieira LM, de Matos HJ et al. Reactional states in multibacillary Hansen disease patients during multidrug therapy. Rev Inst Med Trop Sao Paulo, 1998; 40: 363-370.
3. Croft RP, Nicholls PG, Steyerberg EW et al. A clinical prediction rule for nerve-function impairment in leprosy patients. Lancet, 2000; 355(9215): 1603-1606.
4. Dharmendra, Leprosy Classification. In: RC H (ed). Leprosy, 2nd edn. Churchill-Livingstone, Edinburgh, 1994.
5. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis, 1966; 34: 255-273.
6. Meyers WM, Heggie CD, Kay TL, Staple EM, Kvernes S. The Ridely-Jopling five group classification of leprosy-correlation of parameters of the classification in 1429 leprosy patients. 14th Joint Leprosy Conference; 1979. Int J Lepr.
7. Bjune G, Barnetson RS, Ridley DS, Kronvall G. Lymphocyte transformation test in leprosy; correlation of the response with inflammation of lesions. Clin Exp Immunol, 1976; 25: 85-94.
8. Melsom R, Harboe M, Myrvang B et al. Immunoglobulin class specific antibodies to M. leprae in leprosy patients, including the indeterminate group and healthy contacts as a step in the development of methods for sero-diagnosis of leprosy. Clin Exp Immunol, 1982; 47: 225-233.
9. Yamamura M, Uyemura K, Deans RJ et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science, 1991; 254(5029): 277-279.
10. Krutzik SR, Ochoa MT, Sieling PA et al. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat Med, 2003; 9: 525-532.
11. Ridley DS. Pathogenesis of Leprosy and Related Diseases. Wright, London, 1988.
12. WHO. Chemotherapy of leprosy for control programmes. WHO, Tech Rep Ser, 1982: 675.
13. WHO Expert Committee on Leprosy. Sixth Report. World Health Organ Technical Report Series, No 768, 1988: 1-51.
14. Report of the third meeting of the WHO technical advisory group on the elimination of leprosy. WHO/CDS/CPE/CEE/2002.29; 2002; Geneva: WHO.
15. Buhrer-Sekula S, Visschedijk J, Grossi MA et al. The ML flow test as a point of care test for leprosy control programmes: potential effects on classification of leprosy patients. Lepr Rev, 2007; 78: 70-79.
16. Pardillo FE, Fajardo TT, Abalos RM et al. Methods for the classification of leprosy for treatment purposes. Clin Infect Dis, 2007; 44: 1096-1099.
17. Van Brakel WH, Nicholls PG, Das L et al. The INFIR Cohort Study: assessment of sensory and motor neuropathy in leprosy at baseline. Lepr Rev, 2005; 76: 277-295.
18. Moraes MO, Cardoso CC, Vanderborght PR, Pacheco AG. Genetics of host response in leprosy. Lepr Rev, 2006; 77: 189-202.